ପ୍ରଷ୍ଟେରନ

ପ୍ରଷ୍ଟେରନ
Clinical data
Trade names	Astenile, Cetovister, 17-Chetovis, others
Synonyms	EL-10; GL-701; KYH-3102; Androst-5-en-3β-ol-17-one; 3β-Hydroxyandrost-5-en-17-one; 5,6-Didehydroepiandrosterone; Dehydroisoepiandrosterone
AHFS/Drugs.com	monograph
Routes of; administration	By mouth, vaginal (insert), intramuscular injection (as prasterone enanthate), injection (as prasterone sodium sulfate)
Legal status
Legal status	AU: S4 (Prescription only) ; CA: Schedule IV ; US: Over-the-counter ; EU: Rx-only ;
Pharmacokinetic data
Bioavailability	50%
Metabolism	Liver
Metabolites	• Androsterone; • Etiocholanolone; • @@@2@@@ sulfate; • Androstenedione; • Androstenediol; • Testosterone; • Dihydrotestosterone; • Androstanediol; • Estrone; • Estradiol
Elimination half-life	DHEA: 25 minutes; DHEA-S: 11 hours
Excretion	Urine
Identifiers
	IUPAC name (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one;
Chemical and physical data
Formula	C19H28O2
Molar mass	୨୮୮.୪୩ g·mol−1
3D model (JSmol)	Interactive image;
Melting point	148.5 °C (299.3 °F)
	SMILES O=C3[C@]2(CC[C@@H]1[C@@]4(C(=C/C[C@H]1[C@@H]2CC3)\C[C@@H](O)CC4)C)C;
	InChI InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1 ; Key:FMGSKLZLMKYGDP-USOAJAOKSA-N ;
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Prasterone

ପ୍ରଷ୍ଟେରନ, ଅନ୍ୟ ନାମ ଡିହାଇଡ୍ରୋଏପିଆଣ୍ଡ୍ରୋଷ୍ଟେରୋନ (DHEA ) ଏବଂ ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ଇଣ୍ଟ୍ରୋସା, ହେଉଛି ଏକ ଔଷଧ ଏବଂ ଖାଦ୍ୟ ପରିପୂରକ ।^[୫] ^[୬] ଏକ ଔଷଧ ଭାବରେ ଏହା ଋତୁବନ୍ଦ ହୋଇଥିବା ମହିଳାମାନଙ୍କର ଯୋନୀ ଆଟ୍ରୋଫିର ଚିକିତ୍ସା କରିବା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୫] ଏହି ଉଦ୍ଦେଶ୍ୟରେ ଏହା ଯୋନୀରେ ବ୍ୟବହୃତ ହୁଏ ।^[୫] ଏହା ଆଣ୍ଟି-ଏଜିଙ୍ଗ୍ ଗୁଣଗୁଡିକର ଦାବି ସହିତ ଏକ ସପ୍ଲିମେଣ୍ଟ ଭାବରେ ବିକ୍ରି ହୁଏ ।^[୬]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯୋନୀ ସ୍ରାବ ଏବଂ ଅସ୍ୱାଭାବିକ ପ୍ୟାପ୍ ସ୍ମିଅର ଅନ୍ତର୍ଭୁକ୍ତ ।^[୭] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଓଜନ ପରିବର୍ତ୍ତନ, ବ୍ରଣ, ତେଲିଆ ଚର୍ମ ଏବଂ କେଶ ବୃଦ୍ଧି ହୋଇପାରେ ।^[୮] ^[୬] ଏହା ଏକ ପ୍ରାକୃତିକ ଭାବରେ ଘଟୁଥିବା ଷ୍ଟିରଏଡ୍ ହରମୋନ ଯାହା ଆଣ୍ଡ୍ରୋଜେନ୍ ଏବଂ ଇଷ୍ଟ୍ରୋଜେନରେ ପରିବର୍ତ୍ତିତ ହୁଏ ।^[୯]

୧୯୩୪ ମସିହାରେ ପ୍ରଷ୍ଟେରନ ଆବିଷ୍କୃତ ହୋଇଥିଲା।^[୬] ୨୦୧୮ ମସିହାରେ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଏହାକୁ ଅନୁମୋଦନ କରାଯାଇଥିଲା ।^[୫] ^[୮] ^[୭] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଓଭର-ଦି-କାଉଣ୍ଟର ସପ୍ଲିମେଣ୍ଟର ମାର୍କେଟିଂ ଅନୁମତିପ୍ରାପ୍ତ ।^[୩]

ଆଧାର

1 2 J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–. ISBN 978-1-4757-2085-3. Archived from the original on 22 October 2020. Retrieved 27 September 2021.
↑ James Devillers (27 April 2009). Endocrine Disruption Modeling. CRC Press. pp. 339–. ISBN 978-1-4200-7636-3. Archived from the original on 19 April 2021. Retrieved 27 September 2021.
1 2 3 4 5 6 7 8 9 10 Melanie Johns Cupp; Timothy S. Tracy (10 December 2002). Dietary Supplements: Toxicology and Clinical Pharmacology. Springer Science & Business Media. pp. 123–147. ISBN 978-1-59259-303-3. Archived from the original on 20 August 2020. Retrieved 27 September 2021.
1 2 B.J. Oddens; A. Vermeulen (15 November 1996). Androgens and the Aging Male. CRC Press. pp. 5–. ISBN 978-1-85070-763-9. Archived from the original on 8 March 2021. Retrieved 27 September 2021.
1 2 3 4 "Intrarosa". Archived from the original on 21 March 2021. Retrieved 29 October 2021.
1 2 3 4 Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R (July 2014). "Dehydroepiandrosterone (DHEA): hypes and hopes". Drugs. 74 (11): 1195–207. doi:10.1007/s40265-014-0259-8. PMID 25022952.
1 2 "Prasterone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 29 October 2021.
1 2 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 879. ISBN 978-0857114105.
↑ Prough RA, Clark BJ, Klinge CM (April 2016). "Novel mechanisms for DHEA action". J. Mol. Endocrinol. 56 (3): R139–55. doi:10.1530/JME-16-0013. PMID 26908835.

[Elks2014-1] 1 2 J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–. ISBN 978-1-4757-2085-3. Archived from the original on 22 October 2020. Retrieved 27 September 2021.

[Devillers2009-2] James Devillers (27 April 2009). Endocrine Disruption Modeling. CRC Press. pp. 339–. ISBN 978-1-4200-7636-3. Archived from the original on 19 April 2021. Retrieved 27 September 2021.

[Cup2002-3] 1 2 3 4 5 6 7 8 9 10 Melanie Johns Cupp; Timothy S. Tracy (10 December 2002). Dietary Supplements: Toxicology and Clinical Pharmacology. Springer Science & Business Media. pp. 123–147. ISBN 978-1-59259-303-3. Archived from the original on 20 August 2020. Retrieved 27 September 2021.

[OddensVermeulen1996-4] 1 2 B.J. Oddens; A. Vermeulen (15 November 1996). Androgens and the Aging Male. CRC Press. pp. 5–. ISBN 978-1-85070-763-9. Archived from the original on 8 March 2021. Retrieved 27 September 2021.

[EPAR2021-5] 1 2 3 4 "Intrarosa". Archived from the original on 21 March 2021. Retrieved 29 October 2021.

[Rut2014-6] 1 2 3 4 Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R (July 2014). "Dehydroepiandrosterone (DHEA): hypes and hopes". Drugs. 74 (11): 1195–207. doi:10.1007/s40265-014-0259-8. PMID 25022952.

[AHFS2021-7] 1 2 "Prasterone Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Retrieved 29 October 2021.

[BNF81-8] 1 2 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 879. ISBN 978-0857114105.

[Pro2016-9] Prough RA, Clark BJ, Klinge CM (April 2016). "Novel mechanisms for DHEA action". J. Mol. Endocrinol. 56 (3): R139–55. doi:10.1530/JME-16-0013. PMID 26908835.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]